Parion Sciences Announces Initiation of Phase 2 Clinical Study of P-1037 for the Treatment of Cystic Fibrosis

First Patient with Cystic Fibrosis Enrolled in CLEAN-CF Phase 2 Clinical Trial

Durham, NC (May 6, 2015) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today it has begun enrollment of a phase 2 clinical trial of P-1037 in patients with Cystic Fibrosis (CF).

The trial has been named the “CLEAN-CF” trial which refers to “Clearing Lungs with ENaC inhibition in Cystic Fibrosis”. The CLEAN-CF study will include CF patients regardless of an individual’s genetic mutation. Inhibiting the epithelial sodium channels (ENaC) in the airways with P-1037, an “ENaC blocker,” is expected to re-hydrate the mucus layers, thus restoring airway clearance, improve lung function and, ultimately, reduce exacerbations. P-1037 has demonstrated to be long acting in preclinical models and to have a favorable safety and tolerability profile in the completed Phase 1 studies. The initiation of the Phase 2 clinical trials was supported by an award from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation.

READ THE ENTIRE PRESS RELEASE HERE ►

Parion’s $19.6M Inflow To Help Many Breathe Easier

Mucus.

Non-adolescents generally don’t think much about it until they’re suffering from allergies or a cold. For most people, you might say, ‘snot a big deal.

But a layer of protective mucus in sensitive bodily tissues plays a critical role in keeping our bodies healthy. People who have mucosal surface deficiencies suffer from conditions ranging from dry eye disease to life-threatening pulmonary diseases, including cystic fibrosis (CF), chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis.

READ THE ENTIRE ARTICLE HERE